Psoriasis Patients Who Meditate May Ease Symptoms, Improve QOL
FRIDAY, Oct. 21, 2022 (HealthDay News) — Meditation may help patients manage psoriasis, according to a review published online Sept. 14 in Dermatology and Therapy.Erin Bartholomew, from University of California, San Francisco, and colleagues conducte…
Learn MoreOnline Symptom Checkers Often Not Accurate for ID’ing Skin Rashes
TUESDAY, Oct. 18, 2022 (HealthDay News) — Online symptom checkers are often inaccurate in identifying skin rashes, according to a study published online Oct. 12 in the Journal of the American Academy of Dermatology.Nicholas A. Berry, from the Mayo Cl…
Learn MoreOnline Symptom Checkers Often Not Accurate for ID’ing Skin Rashes
TUESDAY, Oct. 18, 2022 (HealthDay News) — Online symptom checkers are often inaccurate in identifying skin rashes, according to a study published online Oct. 12 in the Journal of the American Academy of Dermatology.Nicholas A. Berry, from the Mayo Cl…
Learn MoreUn medicamento muestra potencial para la esclerodermia, una enfermedad autoinmune
LUNES, 10 de octubre de 2022 (HealthDay News) — Los investigadores informan un éxito temprano con el uso de un medicamento existente para la artritis reumatoide (AR), para tratar la esclerosis sistémica, una afección autoinmune rara pero potencialmen…
Learn MoreLenabasum Studied for Refractory Cutaneous Dermatomyositis
TUESDAY, Oct. 11, 2022 (HealthDay News) — Lenabasum is well tolerated for the treatment of amyopathic dermatomyositis, according to a phase 2 study published online Oct. 1 in the Journal of Investigative Dermatology.Victoria P. Werth, M.D., from the …
Learn MoreDrug Shows Promise Against Autoimmune Disease Scleroderma
MONDAY, Oct. 10, 2022 (HealthDay News) — Researchers report early success with using an existing rheumatoid arthritis (RA) drug to treat systemic sclerosis, a rare but potentially devastating autoimmune condition. The disease, a subset of scleroderma…
Learn MoreFDA Approves Dupixent for Prurigo Nodularis
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration approved Dupixent (dupilumab) as the first treatment for adults with prurigo nodularis, according to Regeneron Pharmaceuticals.Prurigo nodularis, a chronic, debilitating …
Learn MoreFDA Approves Dupixent for Prurigo Nodularis
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration approved Dupixent (dupilumab) as the first treatment for adults with prurigo nodularis, according to Regeneron Pharmaceuticals.Prurigo nodularis, a chronic, debilitating …
Learn MoreFDA Approves Dupixent for Prurigo Nodularis
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration approved Dupixent (dupilumab) as the first treatment for adults with prurigo nodularis, according to Regeneron Pharmaceuticals.Prurigo nodularis, a chronic, debilitating …
Learn More‘Life Changing’: New Drug Eases Severe Eczema in Young Kids
TUESDAY, Sept 20, 2022 (HealthDay News) — Sonia Dhaliwal knows exactly how bad childhood eczema can get.That’s because her young daughter, Ariah Khan, has struggled with a severe case of the skin condition ever since she was a baby.Ariah’s symptoms w…
Learn More